CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)

Launched by UNIVERSITY COLLEGE, LONDON · Dec 16, 2020

Keywords

ClinConnect Summary

The CiproPAL trial is a study looking at whether taking a daily antibiotic called ciprofloxacin can help prevent infections in children who are starting treatment for Acute Lymphoblastic Leukaemia (ALL). This trial is part of a larger study called ALLTogether-1 and aims to see if ciprofloxacin can reduce the number of infections during the first phase of treatment, as well as to understand how it affects the development of antibiotic resistance in bacteria.

To be eligible for this study, children aged between 1 and 17 years who are newly diagnosed with ALL and are beginning their treatment in the UK within the first two weeks can participate, as long as their parent or guardian gives written consent. Participants will be randomly assigned to either receive ciprofloxacin or the usual local care they would typically get. It's important to note that certain children, such as those with specific health conditions or those already on ciprofloxacin, cannot join. This trial is currently open for recruitment, and it aims to provide valuable information on how to better protect young patients from infections during their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Paediatric patients (1-17 years inclusive) with de-novo Acute Lymphoblastic Leukaemia treated on ALLTogether-1 in the UK in the first 5 days of therapy, up to 14 days is acceptable.
• • Written informed consent
• Exclusion Criteria:
• • Non-participants of the ALLTogether-1 trial
• • Patients with Down syndrome who already receive ciprofloxacin prophylaxis
• • Chronic active arthritis
• • Other contraindication to fluoroquinolones